Frontier Biotechnologies Management
Management criteria checks 3/4
Frontier Biotechnologies' CEO is Dong Xie, appointed in Jan 2002, has a tenure of 23.33 years. directly owns 3.72% of the company’s shares, worth CN¥119.04M. The average tenure of the management team and the board of directors is 9.3 years and 6.6 years respectively.
Key information
Dong Xie
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 23.3yrs |
| CEO ownership | 3.7% |
| Management average tenure | 9.3yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
CEO
Dong Xie (58 yo)
23.3yrs
Tenure
CN¥2,262,000
Compensation
Dr. Dong Xie, Ph D founded Frontier Biotechnologies Inc. in 2002 and serves as its Chairman and Chief Scientific Officer since January 2013 and serves as its President since 2025. Prior to co-founding Fron...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP | 9.3yrs | CN¥1.37m | no data | |
| CTO & Director | 12.3yrs | CN¥1.88m | 5.8% CN¥ 185.9m | |
| Supervisor & Deputy GM Administrative Director | no data | CN¥593.80k | no data | |
| Senior Vice President of Marketing & Sales | no data | CN¥1.22m | no data | |
| VP, Deputy GM & Secretary of the Board of Directors | 4.4yrs | CN¥962.00k | no data | |
| Founder | 23.3yrs | CN¥2.26m | 3.72% CN¥ 119.0m | |
| Accounting Supervisor | no data | no data | no data | |
| MD, CBO & Director | less than a year | CN¥2.23m | 5.62% CN¥ 180.1m | |
| C.M.O. | no data | no data | no data | |
| Senior Vice President & Head of Infectious Diseases Therapy Area | no data | no data | no data |
9.3yrs
Average Tenure
54yo
Average Age
Experienced Management: 688221's management team is seasoned and experienced (9.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CTO & Director | 12.3yrs | CN¥1.88m | 5.8% CN¥ 185.9m | |
| Supervisor & Deputy GM Administrative Director | 6.3yrs | CN¥593.80k | no data | |
| Founder | 12.3yrs | CN¥2.26m | 3.72% CN¥ 119.0m | |
| MD, CBO & Director | 12.3yrs | CN¥2.23m | 5.62% CN¥ 180.1m | |
| Independent Director | 6.3yrs | CN¥150.00k | no data | |
| Supervisor | 7yrs | no data | no data | |
| Independent Director | 3yrs | CN¥130.20k | no data | |
| Independent Director | 6.3yrs | CN¥90.70k | no data | |
| Chairman of the Supervisory Board & Purchasing Director | 9.3yrs | CN¥380.60k | no data | |
| Director | 1.3yrs | no data | no data |
6.6yrs
Average Tenure
54.5yo
Average Age
Experienced Board: 688221's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/10 21:53 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Frontier Biotechnologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.